Novo Nordisk faces setbacks with semaglutide in Alzheimer's trials and declining growth. Read here for analyst outlook and why NVO stock is rated Hold now.
Helldivers 2 Major Order deadline approaches. Turing's fate hangs in balance as community battles across three fronts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback